21 results on '"Calvo, Gonzalo"'
Search Results
2. The development of academic CAR T cells
- Author
-
Delgado, Julio, Juan, Manel, Calvo, Gonzalo, and Urbano-Ispizua, Álvaro
- Published
- 2024
- Full Text
- View/download PDF
3. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
- Author
-
Trias, Esteve, Juan, Manel, Urbano-Ispizua, Alvaro, and Calvo, Gonzalo
- Abstract
In February 2021, the ‘Advanced Therapy Medicinal Product’ (ATMP) ARI-0001 (CART19-BE-01), developed at Hospital Clínic de Barcelona (Spain), received authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) under the ‘hospital exemption’ (HE) approval pathway for the treatment of patients aged >25 years with relapsed/refractory (RR) acute lymphoblastic leukemia (ALL). The HE pathway foreseen by the European Regulation establishing the legal framework for ATMPs intended to be placed on the market in the EU, allows access to ATMPs prepared on a non-routine basis, according to quality standards, like a custom-made product for an individual patient. Its use is limited to the same Member State where it was developed, in a hospital under the responsibility of a medical practitioner. HE-ATMPs must comply with national traceability and pharmacovigilance requirements and specific quality standards. HE offers an opportunity to develop ATMPs in close contact with clinical practice, with the quality and rapid access needed by patients and at a lower cost compared to regular market authorization. However, many barriers need to be overcome. Here we discuss relevant aspects of the development and authorization of ARI-0001 in the context of the heterogeneous frame of the European Regulation implementation across the Member States.
- Published
- 2022
- Full Text
- View/download PDF
4. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies
- Author
-
Ortíz-Maldonado, Valentín, Rives, Susana, Castellà, Maria, Alonso-Saladrigues, Anna, Benítez-Ribas, Daniel, Caballero-Baños, Miguel, Baumann, Tycho, Cid, Joan, Garcia-Rey, Enric, Llanos, Cristina, Torrebadell, Montserrat, Villamor, Neus, Giné, Eva, Díaz-Beyá, Marina, Guardia, Laia, Montoro, Mercedes, Català, Albert, Faura, Anna, González, E. Azucena, Español-Rego, Marta, Klein-González, Nela, Alsina, Laia, Castro, Pedro, Jordan, Iolanda, Fernández, Sara, Ramos, Federico, Suñé, Guillermo, Perpiñá, Unai, Canals, Josep M., Lozano, Miquel, Trias, Esteve, Scalise, Andrea, Varea, Sara, Sáez-Peñataro, Joaquín, Torres, Ferran, Calvo, Gonzalo, Esteve, Jordi, Urbano-Ispizua, Álvaro, Juan, Manel, and Delgado, Julio
- Abstract
We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-0001 cells at a dose of 0.4–5 × 106ARI-0001 cells/kg, initially as a single dose and later split into 3 fractions (10%, 30%, and 60%) with full administration depending on the absence of cytokine release syndrome (CRS). 58 patients were included, of which 47 received therapy: 38 with acute lymphoblastic leukemia (ALL), 8 with non-Hodgkin’s lymphoma, and 1 with chronic lymphocytic leukemia. In patients with ALL, grade ≥3 CRS was observed in 13.2% (26.7% before versus 4.3% after the amendment), grade ≥3 neurotoxicity was observed in 2.6%, and the procedure-related mortality was 7.9% at day +100, with no procedure-related deaths after the amendment. The measurable residual disease-negative complete response rate was 71.1% at day +100. Progression-free survival was 47% (95% IC 27%–67%) at 1 year: 51.3% before versus 39.5% after the amendment. Overall survival was 68.6% (95% IC 49.2%–88%) at 1 year. In conclusion, the administration of ARI-0001 cells provided safety and efficacy results that are comparable with other academic or commercially available products. This trial was registered as ClinicalTrials.gov: NCT03144583.
- Published
- 2021
- Full Text
- View/download PDF
5. Systemic Mycoses: A Potential Alert for Complications in COVID-19 Patients
- Author
-
Segrelles-Calvo, Gonzalo, de S Araújo, Glauber R, and Frases, Susana
- Abstract
As the global COVID-19 pandemic spreads worldwide, new challenges arise in the clinical landscape. The need for reliable diagnostic methods, treatments and vaccines for COVID-19 is the major worldwide urgency. While these goals are especially important, the growing risk of co-infections is a major threat not only to the health systems but also to patients’ lives. Although there is still not enough published statistical data, co-infections in COVID-19 patients found that a significant number of patients hospitalized with COVID-19 developed secondary systemic mycoses that led to serious complications and even death. This review will discuss some of these important findings with the major aim to warn the population about the high risk of concomitant systemic mycoses in individuals weakened by COVID-19.
- Published
- 2020
- Full Text
- View/download PDF
6. Changes in root architecture and productivity of melon (Cucumis meloL. cv. Hispano Nunhems) promoted by Glomus iranicumvar. tenuihypharum
- Author
-
Alarcón, Antonio Luis, Gómez-Bellot, María José, Bernabe, Antonio José, Calvo, Gonzalo, and Fernández Martín, Félix
- Abstract
ABSTRACTIn this work, the effect of inoculation with the arbuscular mycorrhizal fungus Glomus iranicumvar. tenuihypharumon the root development and yield of melon plants (Cucumis meloL. cv. Hispano de Nunhems), grown in soil under intensive agriculture for four months, was evaluated. The parameters root length, root volume, area, number of root tips, rhizosphere activity, yield, and crop quality were measured. The inoculated melon plants had an increased percentage of colonisation, which reached 75% at the end of experiment. As a consequence, the inoculated plants exhibited greater rhizospheric activity with higher bacterial and fungal population than the control plants. Inoculation produced a greater volume of roots. It was also observed a higher area of roots with a diameter less than 0.2 mm, and a greater number of tips in roots with a diameter less than 0.5 mm. This suggested a proliferation of lateral roots and significant changes on the root architecture. In addition, these plants had greater fruit number and length, yield, and fruit sugar content than untreated plants. Therefore, the mycorrhizal association had a strong positive effect on the architecture and root activity, which stimulated the capacity for nutrient absorption, resulting in a higher yield and fruit quality.
- Published
- 2020
- Full Text
- View/download PDF
7. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
- Author
-
Gratacós, Jordi, Pontes, Caridad, Juanola, Xavier, Sanz, Jesús, Torres, Ferran, Avendaño, Cristina, Vallano, Antoni, Calvo, Gonzalo, Miguel, Eugenio, and Sanmartí, Raimon
- Abstract
The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded. The trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male, mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1 year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95% CI) − 2.5% (− 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full dose and 2/61 patients (3.3%) assigned to reduced dose (pvalue = 0.164). In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. EU Clinical Trials Registry, EudraCT 2011–005871-18and ClinicalTrials.gov, NCT01604629.
- Published
- 2019
- Full Text
- View/download PDF
8. Restrictive vs Liberal Blood Transfusions for Patients with Acute Myocardial Infarction and Anaemia by Heart Failure Status: An RCT Subgroup Analysis
- Author
-
Ducrocq, Gregory, Cachanado, Marine, Simon, Tabassome, Puymirat, Etienne, Lemesle, Gilles, Lattuca, Benoit, Ariza-Solé, Albert, Silvain, Johanne, Ferrari, Emile, Gonzalez-Juanatey, Jose R., Martínez-Sellés, Manuel, Lermusier, Thibault, Coste, Pierre, Vanzetto, Gerald, Cottin, Yves, Dillinger, Jean G., Calvo, Gonzalo, and Steg, Philippe Gabriel
- Abstract
Red blood cell transfusion can cause fluid overload. We evaluated the interaction between heart failure (HF) at baseline and transfusion strategy on outcomes in acute myocardial infarction (AMI).
- Published
- 2024
- Full Text
- View/download PDF
9. Neumonía bilateral por Ralstonia pickettiien una paciente inmunocompetente
- Author
-
Segrelles-Calvo, Gonzalo, Sánchez Hernández, Ana, and Rey, Laura
- Published
- 2024
- Full Text
- View/download PDF
10. The Grammar of Animacy.
- Author
-
TROSKIE, ELODI and CALVO, GONZALO GARCÍA
- Subjects
ANIMACY (Grammar) ,MODERN languages ,AFRICAN languages ,NATIVE language ,HAWTHORNS - Abstract
There is a tautness to them: the birds, insects, shrubs, and trees stretch out their arms, anxious to climb back into the language they come from. The umbrella thorn tree is known in Afrikaans as the haak-en-steek - "hook and prod." Its Afrikaans name translates to "shiny leaf wait a bit", a nod to the tree's glossy foliage and hooked thorns that easily latch on to your clothes when you walk by. [Extracted from the article]
- Published
- 2023
11. Zampanolide Binding to Tubulin Indicates Cross-Talk of Taxane Site with Colchicine and Nucleotide Sites
- Author
-
Field, Jessica J., Pera, Benet, Gallego, Juan Estévez, Calvo, Enrique, Rodríguez-Salarichs, Javier, Sáez-Calvo, Gonzalo, Zuwerra, Didier, Jordi, Michel, Andreu, José M., Prota, Andrea E., Ménchon, Grégory, Miller, John H., Altmann, Karl-Heinz, and Díaz, J. Fernando
- Abstract
The marine natural product zampanolide and analogues thereof constitute a new chemotype of taxoid site microtubule-stabilizing agents with a covalent mechanism of action. Zampanolide-ligated tubulin has the switch-activation loop (M-loop) in the assembly prone form and, thus, represents an assembly activated state of the protein. In this study, we have characterized the biochemical properties of the covalently modified, activated tubulin dimer, and we have determined the effect of zampanolide on tubulin association and the binding of tubulin ligands at other binding sites. Tubulin activation by zampanolide does not affect its longitudinal oligomerization but does alter its lateral association properties. The covalent binding of zampanolide to β-tubulin affects both the colchicine site, causing a change of the quantum yield of the bound ligand, and the exchangeable nucleotide binding site, reducing the affinity for the nucleotide. While these global effects do not change the binding affinity of 2-methoxy-5-(2,3,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one (MTC) (a reversible binder of the colchicine site), the binding affinity of a fluorescent analogue of GTP (Mant-GTP) at the nucleotide E-site is reduced from 12 ± 2 × 105M–1in the case of unmodified tubulin to 1.4 ± 0.3 × 105M–1in the case of the zampanolide tubulin adduct, indicating signal transmission between the taxane site and the colchicine and nucleotide sites of β-tubulin.
- Published
- 2017
- Full Text
- View/download PDF
12. Periimplantitis apical - presentación de serie de 11 casos clínicos
- Author
-
Stavaru Marinescu, Bogdan, Naval Gías, Luis, and Herrera Calvo, Gonzalo
- Abstract
Evaluar el protocolo quirúrgico y discutir los posibles factores predisponentes de la periimplantitis apical.
- Published
- 2015
- Full Text
- View/download PDF
13. Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements
- Author
-
Ulldemolins, Marta, Soy, Dolors, Llaurado-Serra, Mireia, Vaquer, Sergi, Castro, Pedro, Rodríguez, Alejandro H., Pontes, Caridad, Calvo, Gonzalo, Torres, Antoni, and Martín-Loeches, Ignacio
- Abstract
ABSTRACTMeropenem dosing in critically ill patients with septic shock and continuous renal replacement therapy (CRRT) is complex, with the recommended maintenance doses being 500 mg to 1,000 mg every 8 h (q8h) to every 12 h. This multicenter study aimed to describe the pharmacokinetics (PKs) of meropenem in this population to identify the sources of PK variability and to evaluate different dosing regimens to develop recommendations based on clinical parameters. Thirty patients with septic shock and CRRT receiving meropenem were enrolled (153 plasma samples were tested). A population PK model was developed with data from 24 patients and subsequently validated with data from 6 patients using NONMEM software (v.7.3). The final model was characterized by CL = 3.68 + 0.22 · (residual diuresis/100) and V= 33.00 · (weight/73)2.07, where CL is total body clearance (in liters per hour), residual diuresis is the volume of residual diuresis (in milliliters per 24 h), and Vis the apparent volume of distribution (in liters). CRRT intensity was not identified to be a CL modifier. Monte Carlo simulations showed that to maintain concentrations of the unbound fraction (fu) of drug above the MIC of the bacteria for 40% of dosing interval T(referred to as 40% of the ƒuT>MIC), a meropenem dose of 500 mg q8h as a bolus over 30 min would be sufficient regardless of the residual diuresis. If 100% of the ƒuT>MICwas chosen as the target, oligoanuric patients would require 500 mg q8h as a bolus over 30 min for the treatment of susceptible bacteria (MIC < 2 mg/liter), while patients with preserved diuresis would require the same dose given as an infusion over 3 h. If bacteria with MICs close to the resistance breakpoint (2 to 4 mg/liter) were to be treated with meropenem, a dose of 500 mg every 6 h would be necessary: a bolus over 30 min for oligoanuric patients and an infusion over 3 h for patients with preserved diuresis. Our results suggest that residual diuresis may be an easy and inexpensive tool to help with titration of the meropenem dose and infusion time in this challenging population.
- Published
- 2015
- Full Text
- View/download PDF
14. Heart failure event definitions in drug trials in patients with type 2 diabetes
- Author
-
Sharma, Abhinav, Bhatt, Deepak L, Calvo, Gonzalo, Brown, Nancy J, Zannad, Faiez, and Mentz, Robert J
- Published
- 2016
- Full Text
- View/download PDF
15. Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients
- Author
-
Thiébaut, Rodolphe, El-Sadr, Wafaa M, Friis-Møller, Nina, Rickenbach, Martin, Reiss, Peter, Monforte, Antonella D'Arminio, Morfeldt, Linda, Fontas, Eric, Kirk, Ole, Wit, Stephane De, Calvo, Gonzalo, Law, Matthew G, Dabis, François, Sabin, Caroline A, Lundgren, Jens D, El-Sadr, W, Calvo, G, Dabis, F, Kirk, O, Law, M, Monforte, A d'Arminio, Morfeldt, L, Pradier, C, Reiss, P, Weber, R, Wit, S De, Zaheri, S, Gras, L, Thiébaut, R, Balestre, E, Petoumenos, K, Mateu, S, Torres, F, Sommereijns, B, Poll, B, Bartsch, G, Thompsen, G, Kjær, J, Pezzotti, P, Fontas, E, Caissotti, C, Sundström, A, Thulin, G, Rickenbach, M, Keiser, O, Sabin, CA, Phillips, AN, Collins, S, Friis-Møller, N, Worm, S W, Sawitz, A, Lundgren, JD, Mertenskoetter, T, Loeliger, E, Tressler, R, and Weller, I
- Abstract
Objective We assessed predictors of changes in systolic (SBP) and diastolic (DBP) blood pressure during follow-up and of the development of hypertension in HIV-infected individuals.Methods International cohort collaborative study (D:A:D) of established prospective cohorts of HIV-1-infected patients. Longitudinal analysis of changes in blood pressure (BP) was performed using mixed effects models in 17170 patients. Predictors of development of hypertension during follow-up (systolic BP =140 and/or diastolic BP =90 mmHg or initiation of antihypertensive treatment) were assessed using Cox models in 8 984 patients with a normal BP level at baseline.Results 73548 BP measurements with a median of 4 per patient (interquartile range [IQR]: 2–6) were recorded over a median follow-up of 2.3 years (IQR: 1.5–2.6). Risk factors significantly associated with a development of higher systolic BP and diastolic BP (differences =5 mmHg and P-values <0.001) during follow-up were: older age, male sex, higher body mass index (BMI) and use of BP-lowering drugs. In patients with normal BP at baseline, 1186 developed hypertension for an incidence of 72.1 per 1000 person-years (95% confidence interval: 68.2–76.0). Factors associated with development of hypertension were: male sex, higher BMI, older age, higher BP at baseline, high total cholesterol and clinical lipodystrophy. Cumulative duration of exposure to nucleoside reverse transcriptase inhibitors (P=0.75), protease inhibitors (P=0.92) as well as type of antiretroviral treatment at baseline (P=0.18) were not associated with a higher risk of hypertension. Cumulative duration of exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was significantly associated with lower risk of hypertension (hazard ratio=0.78 and 0.67 for those treated =10 months and >10 months compared with no exposure; P=0.005).Conclusions Increased blood pressure in HIV-infected individuals is associated with established risk factors for hypertension. There was no evidence for an independent deleterious effect of any class of antiretroviral drugs on BP, although the use of NNRTIs was associated with a lower risk of development of hypertension.
- Published
- 2005
- Full Text
- View/download PDF
16. Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy Volunteers
- Author
-
Calvo, Gonzalo, García-Gea, Consuelo, Luque, Antonio, Morte, Adelaida, Dal-Ré, Rafael, and Barbanoj, Manel
- Abstract
This investigation aimed to provide evidence on the lack of pharmacokinetic interaction of paroxetine (20 mg/d) and alprazolam (1 mg/d) in combined therapy. In addition, the central effects of both drugs when administered alone and in combination were assessed to rule out any relevant synergistic depressant central effect. Twenty-five healthy young adult volunteers participated in a double-blind, double-dummy, placebo-controlled, repeated dose (15 days), 4-period crossover study. Each subject received each of 4 treatment sequences (ie, paroxetine-alprazolam placebo, alprazolam-paroxetine placebo, paroxetine-alprazolam, and paroxetine placebo-alprazolam placebo) in randomized order. The ratios for area under the curve within a dosing interval and maximum plasma concentration of the paroxetine plus alprazolam sequence to single agent paroxetine were 1.07 (90% confidence interval = 0.99 to 1.16) and 1.05 (90% confidence interval = 0.97 to 1.13), respectively, with no statistically significant differences between the 2 treatments. Similarly, for alprazolam, ratios for the combined to the single treatment sequence were 0.99 (90% confidence interval = 0.93 to 1.05) and 1.00 (90% confidence interval = 0.94 to 1.07) for area under the curve within a dosing interval and maximum plasma concentration, respectively, showing no evidence for interaction. Comparative pharmacodynamics on the combination was assessed using 6 Psychomotor Performance Tests and 5 Visual Analogue Scales focused on mood variables. Alprazolam and paroxetine plus alprazolam induced similar and significant performance impairment and sedation after both single and repeated dose administration, being less evident on day 15. After dosing, paroxetine plus alprazolam showed a lower recovery pattern than alprazolam alone, especially on day 15. No treatment sequence showed cumulative effects after repeated dose administration. Psychomotor Performance Tests and Visual Analogue Scales data suggested lack of pharmacodynamic interactions. Accordingly, study results showed no evidence for pharmacologic interactions between paroxetine and alprazolam at steady state. The most commonly reported adverse event was drowsiness, with a higher incidence under both single and combined alprazolam treatments.
- Published
- 2004
- Full Text
- View/download PDF
17. Nitrendipine and Enalapril Combination Therapy in Mild to Moderate Hypertension Assessment of Dose-Response Relationship by a Clinical Trial of Factorial Design
- Author
-
Roca-Cusachs, Alejandro, Torres, Ferran, Horas, Manuel, Ríos, José, Calvo, Gonzalo, Delgadillo, Joaquín, and Terán, Maite
- Abstract
Hypertension is an important cardiovascular risk factor and the goal of its pharmacologic treatment is to reduce morbidity and mortality. Treatment is usually initiated with a low dose of a single agent and titrated to a higher dose as required. As many as 50 of patients require the addition of a second agent to achieve satisfactory blood pressure control. The aim of this study was to assess the dose-response relationship of nitrendipine and enalapril alone or in fixed combination in the treatment of mild to moderate hypertension. A total of 496 patients were enrolled in a multicenter, randomized, double-blind, factorial-design, parallel-group clinical trial comparing placebo, nitrendipine (5, 10, and 20 mg) and enalapril (5, 10, and 20 mg) alone or in combination. After a single-blind, 2-week placebo run-in period, 414 patients whose diastolic blood pressure ranged between 90–109 mm Hg were randomly assigned to a treatment group. The combination of nitrendipine and enalapril, particularly regimens including nitrendipine 20 mg and enalapril 5 or 10 mg, were significantly superior to both monotherapies; mean diastolic blood pressure reductions from baseline to last visit were −12.5 and −14.3 mm Hg, respectively. Response surface analysis provided further evidence that these combinations were optimal in terms of anti-hypertensive efficacy. All treatments were well tolerated and the incidence of adverse events did not differ significantly between groups. In summary, the anti-hypertensive efficacy of the combination was found to be superior to both monotherapies at any doses. The dose combination achieving the greatest blood pressure reduction was nitrendipine 20 mg and enalapril 10 mg.
- Published
- 2001
18. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion
- Author
-
Zannad, Faiez, Stough, Wendy Gattis, Lipicky, Raymond J., Tamargo, Juan, Bakris, George L., Borer, Jeffrey S., Alonso García, Maria de los Angeles, Hadjadj, Samy, Koenig, Wolfgang, Kupfer, Stuart, McCullough, Peter A., Mosenzon, Ofri, Pocock, Stuart, Scheen, André J., Sourij, Harald, Van der Schueren, Bart, Stahre, Christina, White, William B., and Calvo, Gonzalo
- Abstract
The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all new diabetes mellitus therapies remains justified. Given the burden of cardiovascular disease in patients with diabetes, the focus should shift towards cardiovascular outcome studies designed to evaluate efficacy (i.e. to determine the efficacy of a drug over placebo or standard care) rather than demonstrating that risk is not increased by a pre-specified safety margin. All stakeholders are responsible for ensuring that new drug approvals occur under conditions of appropriate safety and effectiveness. It is also a shared responsibility to avoid unnecessary hurdles that may compromise access to useful drugs and threaten the sustainability of health systems. It is critical to renew this debate so that stakeholders can collectively determine the optimal approach for developing new drugs to treat type 2 diabetes mellitus.
- Published
- 2016
- Full Text
- View/download PDF
19. Inhaled Tranexamic Acid as an Alternative for Hemoptysis Treatment
- Author
-
Segrelles Calvo, Gonzalo, De Granda-Orive, Ignacio, and López Padilla, Daniel
- Published
- 2016
- Full Text
- View/download PDF
20. NT-proBNP as Prognostic Biomarker in Patients With COPD Exacerbations and Respiratory Acidosis
- Author
-
Castillo, Elena Garcia, Alonso Pérez, Tamara, Calvo, Gonzalo Segrelles, Naranjo, Olga Rajas, Zamora García, Enrique, and Ancochea, Julio
- Published
- 2014
- Full Text
- View/download PDF
21. Hypertension in HIV-infected patients
- Author
-
Thiébaut, Rodolphe, El-Sadr, Wafaa M, Friis-Møller, Nina, Rickenbach, Martin, Reiss, Peter, Monforte, Antonella D'Arminio, Morfeldt, Linda, Fontas, Eric, Kirk, Ole, De Wit, Stephane, Calvo, Gonzalo, Law, Matthew G, Dabis, François, Sabin, Caroline A, and Lundgren, Jens D
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.